Small-molecule tyrosine kinase inhibitors (TKIs) [54], such as imatinib, dasatinib, nilotinib and ponatinib, have been developed to treat CML by blocking the kinase structural domain of the BCR-ABL oncoprotein. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.